NCT01804140View on ClinicalTrials.gov

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

CompletedOBSERVATIONAL

Enrollment

662

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Multiple Myeloma, Neoplasms

Trial Locations (20)

34471

Ocala

37232

Nashville

55125

Woodbury

65201

Columbia

75231

Dallas

75237

Dallas

75246

Dallas

75702

Tyler

76210

Denton

78503

McAllen

78705

Austin

79106

Amarillo

80218

Denver

85704

Tucson

86336

Sedona

89169

Las Vegas

91505

Burbank

91730

Rancho Cucamonga

98902

Yakima

99204

Spokane

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT01804140 - A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) | Biotech Hunter | Biotech Hunter